Gavi Support for Typhoid Conjugate Vaccines : Moving From Global Investments to Country Introduction
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America..
Nine years elapsed between Gavi's investment decision to support typhoid conjugate vaccines (TCVs) in 2008 and Gavi support becoming available for countries to introduce TCV. The protracted path toward Gavi support for TCV highlights the challenges of vaccine development for lower-income countries and the importance of Gavi engagement as early as possible in product development processes to support the alignment of manufacturing, global policy, and program implementation. Early engagement would provide inputs to inform strategic vaccine investment decisions that transition more efficiently toward country implementation. Several countries have been approved for Gavi support to introduce TCV in 2019-2020. The paucity of generalizable typhoid epidemiological data in early introducing countries has reinforced the need for continued evidence generation regarding typhoid epidemiology and TCV impact. This has led to the development of guidance and tools to support country decision making for TCV introduction based on enhanced understanding of local typhoid burden and risk.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 71(2020), Suppl 2 vom: 29. Juli, Seite S160-S164 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soble, Adam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Enteric fever |
|---|
| Anmerkungen: |
Date Completed 27.04.2021 Date Revised 27.04.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa342 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313009171 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313009171 | ||
| 003 | DE-627 | ||
| 005 | 20231225145639.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa342 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313009171 | ||
| 035 | |a (NLM)32725236 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soble, Adam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gavi Support for Typhoid Conjugate Vaccines |b Moving From Global Investments to Country Introduction |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2021 | ||
| 500 | |a Date Revised 27.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a Nine years elapsed between Gavi's investment decision to support typhoid conjugate vaccines (TCVs) in 2008 and Gavi support becoming available for countries to introduce TCV. The protracted path toward Gavi support for TCV highlights the challenges of vaccine development for lower-income countries and the importance of Gavi engagement as early as possible in product development processes to support the alignment of manufacturing, global policy, and program implementation. Early engagement would provide inputs to inform strategic vaccine investment decisions that transition more efficiently toward country implementation. Several countries have been approved for Gavi support to introduce TCV in 2019-2020. The paucity of generalizable typhoid epidemiological data in early introducing countries has reinforced the need for continued evidence generation regarding typhoid epidemiology and TCV impact. This has led to the development of guidance and tools to support country decision making for TCV introduction based on enhanced understanding of local typhoid burden and risk | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a enteric fever | |
| 650 | 4 | |a global health | |
| 650 | 4 | |a immunizations | |
| 650 | 4 | |a typhoid conjugate vaccine | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a Typhoid-Paratyphoid Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Conjugate |2 NLM | |
| 700 | 1 | |a Patel, Zeenat |e verfasserin |4 aut | |
| 700 | 1 | |a Sosler, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Hampton, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Hope |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 71(2020), Suppl 2 vom: 29. Juli, Seite S160-S164 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:Suppl 2 |g day:29 |g month:07 |g pages:S160-S164 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa342 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2020 |e Suppl 2 |b 29 |c 07 |h S160-S164 | ||